In a study in Taiwan, researchers looked at whether nattokinase could reduce factors of blood clotting and lipids that are associated with increased risks of cardiovascular disease.
The study used the following groups of people:
- healthy volunteers.
- patients with cardiovascular disease.
- patients undergoing dialysis.
Everyone took two capsules of nattokinase orally per day for 2 months. Each capsule contained 2000 fibrinolysis units.
Results showed that plasma levels of 3 coagulating factors continuously declined during the study.
After two months:
In the Healthy Group, the decrease in these factors were fibrinogen (9%), factor VII (14%), factor VIII (17%).
In the Cardiovascular Group, the decrease in these factors were fibrinogen (7%), factor VII (13%), factor VIII (19%).
In the Dialysis Group, the decrease in these factors were fibrinogen (10%), factor VII (7%), factor VIII (19%).
Blood lipids were unaffected by nattokinase. There was also no change in uric acid or any side-effects observed during the investigation.
This study indicates that orally taken nattokinase can reduce clotting factors in the blood, and therefore help patients with cardiovascular disease.
Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects.
Hsia CH, Shen MC, Lin JS, Wen YK, Hwang KL, Cham TM, Yang NC.
Nutr Res. 2009 Mar;29(3):190-6.